DBV Technologies reported $361M in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.57B 100M Nov/2026
Alnylam Pharmaceuticals USD 33.02B 7.17B Sep/2026
Amarin USD 290M 51M Dec/2025
BioCryst Pharmaceuticals USD 2.54B 880M Jun/2026
BioMarin Pharmaceutical USD 10.68B 936M Nov/2026
DBV Technologies USD 739M 491M Sep/2026
Halozyme Therapeutics USD 15.62B 3.09B Nov/2026
Incyte USD 24.6B 1.95B Sep/2026
Insmed USD 24.93B 1.82B Sep/2026
Ionis Pharmaceuticals USD 4.24B 3.18B Nov/2026
Neurocrine Biosciences USD 16.38B 1.96B Nov/2026
Sarepta Therapeutics USD 1.65B 276M Nov/2026
Ultragenyx Pharmaceutical USD 1.37B 108M Nov/2026
United Therapeutics USD 28.64B 5.4B Nov/2026